Posted by Michael Wonder on 07 Nov 2019
Endoceutics receives Health Canada approval for Intrarosa
6 November 2019 - The first innovative drug for the treatment of vulvovaginal atrophy with prasterone.
Endoceutics is happy to announce the approval of Intrarosa by Health Canada for the treatment of post-menopausal vulvovaginal atrophy.
Intrarosa is offered as a vaginal ovule containing 6.5 mg of prasterone.
